Rodriguez-Flores et al.

NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34

17 June 2024

1

Title

2 3 NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke 4 5 Authors 6 Juan L. Rodriguez-Flores¹, Shareef Khalid^{2,3}, Neelroop Parikshak¹, Asif Rasheed³, Bin Ye¹, 7 Manav Kapoor¹, Joshua Backman¹, Farshid Sepehrband¹, Silvio Alessandro DiGioia⁴, Sahar 8 Gelfman¹, Tanima De¹, Nilanjana Banerjee¹, Deepika Sharma¹, Hector Martinez⁴, Sofia 9 Castaneda⁵, David D'Ambrosio⁴, Xingmin A. Zhang¹, Pengcheng Xun⁴, Ellen Tsai⁶, I-Chun 10 Tsai⁴, Regeneron Genetics Center¹, Maleeha Zaman Khan³, Muhammad Jahanzaib³, 11 Muhammad Rehan Mian³, Muhammad Bilal Liaqat³, Khalid Mahmood⁷, Tanvir Us Salam⁸, 12 Muhammad Hussain⁸, Javed Igbal⁹, Faizan Aslam¹⁰, Michael N. Cantor¹, Gannie Tzoneva¹, 13 John Overton¹, Jonathan Marchini¹, Jeff Reid¹, Aris Baras¹, Niek Verweij¹, Luca A. Lotta¹, 14 15 Giovanni Coppola¹, Katia Karalis¹, Aris Economides¹, Sergio Fazio⁴, Wolfgang Liedtke⁴, John Danesh¹¹, Ayeesha Kamal¹², Philippe Frossard³, Thomas Coleman¹, Alan R. Shuldiner¹, 16 Danish Saleheen^{2,3} 17 18 19 Affiliations 20 ¹ Regeneron Genetics Center, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA 21 ^{2.} Columbia University, New York, NY, USA 22 ^{3.} Center for Non-Communicable Diseases, Karachi, Pakistan 23 ⁴ Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA 24 ⁵ Rye Country Day School, Rye, NY, USA 25 26 ^{6.} University of California at Los Angeles, Los Angeles, CA, USA ^{7.} Dow University of Health Sciences and Civil Hospital, Karachi, Pakistan 27 28 ^{8.} Lahore General Hospital, Lahore, Pakistan ⁹ Department of Neurology, Allied Hospital, Faisalabad, Pakistan. 29 ^{10.} Department of Neurology, Aziz Fatima Hospital, Faisalabad, Pakistan. 30 31 ^{11.} Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. ¹². Section of Neurology, Department of Medicine, Aga Khan University, Karachi, Pakistan. 32 33 34 Correspondence 35 36 Danish Saleheen, danish.saleheen@cncdpk.com 37 Alan Shuldiner, alan.shuldiner@regeneron.com 38

2

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

39

40

Abstract

- 41 The genetic factors of stroke in South Asians are largely unexplored. Exome-wide sequencing
- 42 and association analysis (ExWAS) in 75 K Pakistanis identified
- 43 NM_000435.3(NOTCH3):c.3691C>T, encoding the missense amino acid substitution
- 44 p.Arg1231Cys, enriched in South Asians (alternate allele frequency = 0.58% compared to
- 45 0.019% in Western Europeans), and associated with subcortical hemorrhagic stroke [odds ratio
- 46 (OR) = 3.39,95% confidence interval (CI) = [2.26, 5.10], p value = 3.87×10^{-9}), and all strokes
- 47 (OR [CI] = 2.30 [1.77, 3.01], p value = 7.79×10^{-10}). *NOTCH3* p.Arg231Cys was strongly
- 48 associated with white matter hyperintensity on MRI in United Kingdom Biobank (UKB)
- 49 participants (effect [95% CI] in SD units = 1.1 [0.61, 1.5], p value = 3.0×10^{-6}). The variant is
- 50 attributable for approximately 2.0% of hemorrhagic strokes and 1.1% of all strokes in South
- 51 Asians. These findings highlight the value of diversity in genetic studies and have major
- 52 implications for genomic medicine and therapeutic development in South Asian populations.

53

Rodriguez-Flores et al. NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

3

54

55

Introduction

56 Pakistan, a country in South Asia, comprises over 231 million inhabitants. It is the fifth most

57 populous country in the world with diverse ancestral backgrounds from South and Central Asia,

58 West Asia, and Africa. Pakistan, and in general South Asia, represents an understudied region in

59 large-scale genetic studies [1], thus providing an opportunity for novel discoveries of the genetic

- 60 basis of diseases.
- 61

62 Stroke is a leading cause of death globally [2], and epidemiological studies suggest an elevated

incidence and prevalence of stroke in Pakistan [2, 3] relative to Europe. The disparities in 63 64

incidence and prevalence between Pakistan and Europe could be due to many factors, including 65 difference in access to healthcare facilities with high-quality diagnostic capabilities and public

66 health awareness and education. These disparities also may reflect differences in prevalence of

risk factors such as hypertension and diabetes, lifestyle factors such as diet, physical activity and 67

68 smoking, and genetic predispositions [4-7]. Studies of the genetic underpinnings of stroke in

69 Pakistani populations have been limited, making this understudied population an opportune

70 venue for stroke exome-wide sequencing and association studies (ExWAS).

71

72 At least 9 rare monogenic disorders are characterized by increased stroke risk, such as cerebral

73 autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) 74 due to mutations in NOTCH3 [8]. CADASIL is distinct from other hereditary stroke diseases

75 because it is characterized by vascular smooth muscle cell (VSMC) degeneration in small

76 arteries and accumulation of protein aggregates known as granular osmophilic material (GOM)

77 that contain aggregates of misfolded NOTCH3 extracellular domain (ECD). The more common

78 forms of stroke are likely polygenic with substantial contributions from behavioral and

79 environmental factors as well as age. Major risk factors include high systolic blood pressure,

80 high body mass index, hyperlipidemia, elevated glucose, and smoking [9]. Recent genome-wide

81 association studies (GWAS) identified single nucleotide variants (SNVs) in more than 28 loci

82 associated with stroke [10]. These variants are common non-coding variants with small effect

83 sizes and were identified in predominantly European ancestry populations.

84

85 The aim of this study was to identify protein coding deleterious missense or loss-of-function

86 (LoF) variants associated with stroke phenotypes in the Pakistani population. We performed

87 exome sequencing in a 31 K discovery cohort consisting of 5,135 stroke cases and 26,602

88 controls of Pakistani origin. ExWAS identified NM_000435.3(NOTCH3):c.3691C>T, encoding

89 the missense amino acid substitution p.Arg1231Cys, with an approximately three-fold increased

90 risk of hemorrhagic stroke in heterozygotes. Follow-up meta-analysis of 61 K Pakistani

91 (including an additional 160 cases and 30,239 controls) provided further support for association

92 of NOTCH3 p.Arg1231Cys with stroke (combined ischemic and hemorrhagic). This variant was

93 present in approximately 1% of Pakistani and was markedly enriched with respect to Europeans

94 in multiple South Asian (SAS) and West Asian (WAS) (also referred to as Greater Middle

95 Eastern [11]) populations ranging from Turkey to India. The variant was estimated to explain up

96 to 1.1% of strokes and 2.0% of hemorrhagic strokes in South Asia, a region having a population 97

of > 2 billion people, thus having significant medical implications in these very large yet

- 98 understudied populations and their global diaspora.
- 99

Rodriguez-Flores et al. NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34

	Version 54 17 June 2024
100	17 June 2024
101	
102	
102	Results
103	Kesuts
105	FyWAS in the Pakistan Canomics Resource (PCR) discovery cohort identifies a markedly
105	enriched missense variant in <i>NOTCH3</i> associated with stroke
10/	Characteristics of the n 5 125 study asses and n 26 602 controls in the discovery school on
100	Characteristics of the $n = 3,153$ stroke cases and $n = 20,002$ controls in the discovery conort are
109 110	prevalence of known risk factors for vascular disease including hypertension, diabetes,
111	myocardial infarction, and tobacco use (all $p < 0.01$). As expected, in this cohort ascertained for
112	stroke, most cases were ischemic strokes and most hemorrhagic strokes were subcortical
113	(Supplementary Figures 1 and 2, Supplementary Table 1).
114	
115	Case:control ExWAS for all stroke cases and 4 stroke subtypes with sufficient case counts to
116	provide statistical power (Supplementary Table 1) identified a genome-wide significant (p value
117	< 5.0x10 ⁻⁸) association for NM_000435.3(NOTCH3):c.3691C>T (rs201680145), encoding the
118	missense amino acid substitution p.Arg1231Cys, with subcortical hemorrhagic stroke (OR [95%
119	CI] = $3.39 [2.26, 5.1]$, p value = 3.87×10^{-9} ; AAF = 0.58%) (Figure 1B, Supplementary Table 1
120	and Supplementary Figures 3 and, 4). The p.Arg1231Cys variant also showed evidence for
121	association with all strokes combined (OR [95% CI] = 2.18 [1.65, 2.89], p value = 4.44×10^{-8})
122	and other sub-categories of stroke (Supplementary Table 2). No other variants in the locus were
123	associated with stroke (Figure 1C). We did not observe an association between p.Arg1231Cys
124	and history of hypertension, elevated systolic or diastolic blood pressure, or smoking, known
125	major risk factors for stroke (Supplementary Tables 3 and 4), and inclusion of these risk factors
126	in regression analysis did not appreciably alter the effect of p.Arg1231Cys on stroke risk
127	(Supplementary Table 5).
128	
129	<i>NOTCH3</i> encodes Notch Receptor 3, a transmembrane signaling protein and part of an
130	evolutionarily conserved family that plays a pielotropic role in cell-cell interaction and neural
131	development [12]. The extra-cellular domain (ECD) of <i>NOTCH3</i> consists of 34 Epidermal
132	Growth Factor-like repeat (EGFr) domains [15], each containing o Cysteine (Cys) residues that
133	domaina aquas alassical CADASIL a highly paratrant rare autocomal dominant diagona
134	domains cause classical CADASIL, a highly penetrant rare autosomal dominant disease
133	behavioral abanges [8]. The Cus altering variant associated with strokes in this study.
130	p Arg1221Cyc, acourt in the 21 st ECEr [14] and is predicted deleterious (Supplementary Table
137	6) Stroke asses betarorugous for p Arg1221Cus and stroke asses without the variant ware
130	similar with respect to age, age of stroke onset, type of stroke, and stroke risk factors, suggesting
1/0	a milder form of CADASIL not obviously clinically distinguishable from common forms of
1/1	stroke in this population, although a detailed history for migraine or other manifestations of
1/17	CADASIL were not available (Table 1)
142	
144	Replication and Meta Analysis in PGR
145	

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

5

30,239 controls) were sequenced by CNCD. Replication of the association was observed in this independent cohort (OR [95% CI] = 3.49 [1.56, 7.83], p value = 5.00×10^{-3} . Meta-analysis for all strokes in the combined 61 K cohort achieved a genome-wide significant p value (OR [95% CI]) = 2.30 [1.76, 2.99], p value = 7.08×10^{-10}) (Figure 3).

An additional 30 K of whom self-reported stroke case:control status was obtained (160 cases and

150 151

146

147

148 149

152 **Recall by Genotype**

153

154 A total of 12 p.Arg1231Cys homozygotes from 9 nuclear families were identified in the PGR,

- 155 including 9 discovery cohort probands and 3 follow-up cohort relatives identified through a 156 callback of 128 call-back participants. Baseline characteristics of the 12 homozygotes are shown
- 157 in Supplementary Table 7. Three of twelve (25%) homozygotes had a history of stroke; of note,
- all with stroke were >65 years of age while all without a history of stroke were <55 years of age.
- 159
- 160 Eight out of twelve (66%) p.Arg1231Cys homozygotes had a history of hypertension. Among
- 161 the 128 callback participants, both systolic and diastolic blood pressure were trending higher
- 162 (Supplementary Table 8). While there was no association with hypertension in the discovery
- 163 cohort, p.Arg1231Cys homozygotes in the PGR had nominally higher diastolic blood pressure
- 164 than heterozygotes or homozygous reference individuals (median = 95 mmHg, interquartile
- 165 range 86 to 100; heterozygotes (median = 80 mmHg, interquartile range = 80 to 90), p value =
- 166 0.016 (Supplementary Table 9).
- 167

168 Allele Frequency and Population Attributable Risk

169

170 The allele frequency of p.Arg1231Cys was 1.1% across the PGR 75 K, equivalent to a

- 171 population prevalence of 1 in 46. After removing cases recruited for cardiovascular diseases
- 172 (individuals enrolled at time of acute stroke, MI, and heart failure), the allele frequency of the
- variant was 0.51%, equivalent to a population prevalence of 1 in 98. This frequency was orders
- 174 of magnitude higher relative to exomes of European ancestry from UK Biobank (AAF =
- 175 0.019%), corresponding to a population prevalence of 1 in 2,614). The variant was enriched
- 176 (AAF > 0.1%) in other South Asian and West Asian populations [15] both within and outside of
- 177 Pakistan (Supplementary Data, Supplementary Tables 10 and 11, Supplementary Figure 5).
- 178

We estimate that 2.0% [bootstrap 95% CI based on 10,000 resamples: 1.0% to 2.9%] of

- 180 hemorrhagic strokes and 1.1% [bootstrap 95% CI based on 10,000 resamples: 0.6% to 1.6%] of
- all strokes in the Pakistani population are attributable to p.Arg1231Cys. Thus, this variant is a
- 182 common cause of strokes in SAS and WAS populations, a finding that has implications for
- 183 medical care as well as global health in these populations.
- 184

185 Suggestive Associations at Other Loci

- 186
- 187 Although *NOTCH3* p.Arg1231Cys was the only variant associated with stroke at a genome-wide
- 188 significant p value below 5.0×10^{-8} , there were a total of 9 associations (5 loci) with p values
- below 1.0×10^{-6} and at least 10 variant carriers (Supplementary Table 12). In addition to
- 190 *NOTCH3*, these included one known locus previously associated with stroke in a recent GWAS,
- 191 lymphocyte specific protein *LSP1* [10].

The LSP1 locus variant with suggestive association with intracerebral hemorrhagic stroke in this

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

192 193

194 study was a common intronic variant (rs661348, OR [95% CI] = 1.3 [1.2, 1.4], p value = 8.0×10^{-1} 195 ⁸, AAF = 0.27). While rs661348 was not previously associated with stroke, two common non-196 coding variants in the LSP1 locus were previously reported to be associated with stroke 197 (rs569550 and rs1973765) [10]. Both variants were in linkage disequilibrium with rs661348 ($r^2 > 10^{-1}$ 198 0.4 in 10 K unrelated PGR participants). A test of association for rs661348 conditional on these 199 variants reduced the strength of the association for rs661348 to nominal (8.83×10^{-4}) 200 (Supplementary Table 13), suggesting that rs661348 represents the same known stroke risk locus. The LSP1 locus was previously reported to be associated with hypertension [16]. In 201 202 PGR there was a nominal association with hypertension (rs661348, OR [95% CI] = 1.0 [1.0, 1.1], p value = 2.61×10^{-2}) (Supplementary Tables 14 and 15) also observed in UKB (OR [95% 203 CI] = 1.0 [1.0, 1.1], p value = 8.05x10⁻²⁵ (Supplementary Tables 15 and 16). 204

205

206 NOTCH3 p.Arg1231Cys is associated with stroke and CADASIL-like phenotypes in UK 207 Biobank

208

- To investigate stroke and CADASIL-related phenotypes in an independent cohort, UK Biobank
 data was reviewed for associations with *NOTCH3* p.Arg1231Cys. A total of 255 heterozygotes
- for *NOTCH3* p.Arg1231Cys were observed in 450 K exome-sequenced individuals from this
- predominantly European cohort, with a markedly lower allele frequency (AAF = 0.019%)
- 213 (Supplementary Table 18). Phenome-wide association (PheWAS) of 10,168 phenotypes revealed
- nominally significant association of p.Arg1231Cys with ischemic stroke (OR [95%CI] = 4.0
- 215 [1.9, 8.6]), p value = 4.1×10^{-4}), all strokes combined (OR [95% CI] = 1.9 [1.1, 3.5], p value =
- 216 0.031), hypertension (ICD 10 code I10) (OR [95% CI] = 1.5 [1.1, 2.2], p value = 0.019), and
- 217 recurrent major depression (OR [95% CI] = 3.2 [1.5, 6.8], p value = 0.0031) (Supplementary
- Table 19). No association was observed for hemorrhagic stroke, migraine, dementia, mood
- changes, Alzheimer's disease, or urinary incontinence. The lack of association (p value = 0.066) with homorrhadia stroke in LIKP. Europeans was likely due to low statistical power sizes the
- with hemorrhagic stroke in UKB Europeans was likely due to low statistical power, given the lower variant allele frequency and lower hemorrhagic stroke prevalence in UKB compared to
- PGR. Nonetheless, the odds ratio (OR [95% CI] = 5.8 [0.88, 39.1]) was high.
- 223
- In addition to recurrent strokes, brain white matter loss is a major and early phenotype
- characteristic of CADASIL that is focused on particular brain regions [8, 14]. *NOTCH3*
- p.Arg1231Cys was strongly associated with a cluster of brain MRI quantitative phenotypes, e.g.,
- total volume of white matter hyperintensities (WMH) from T1 and T2 FLAIR images (effect
- 228 [95% CI] in SD units = 1.1 [0.61, 1.5], p value = 3.0×10^{-6}) with carriers having 7.4 cm³ more
- 229 WMH volume than controls (Supplementary Figure 6 and Supplementary Table 20). The most
- prominent alterations in WMH in p.Arg1231Cys carriers were observed in the centrum
- 231 semiovale and periventricular white matter (Supplementary Figure 7). Taken together, these
- 232 results demonstrate *NOTCH3* p.Arg1231Cys carriers have increased risk of established markers
- of small vessel disease and clinical phenotypes observed in CADASIL [8].
- 234

235 Pathogenic burden of all Cys-altering variants within *NOTCH3* EGFr domains specifically

- 236 associated with CADASIL phenotypes in UK Biobank
- 237

Burden test analysis allows for increased statistical power to detect association by combining

CADASIL are limited to variants that add or remove a Cysteine (Cys-altering) in NOTCH3 EGFr

domains normally containing 6 Cysteines. Furthermore, patients with Cys-altering variants in the

first 6 EGFr domains have more severe symptoms than in EGFr domains 7 to 34 [14, 17, 18],

including larger regions of brain white matter loss [19], more granular osmophilic material

signal across multiple rare variants. Prior studies have shown that pathogenic variants in

Rodriguez-Flores et al. NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

(GOM) aggregates in blood vessels [19], and worse prognosis [14].

7

246 In order to test these hypotheses, a set of custom gene burden tests were designed and compared 247 to single variant test results for NOTCH3 p.Arg1231Cys. In UKB, 758 individuals carried one of 248 98 unique Cys-altering variants across the 34 EGFr domains in NOTCH3 (Supplementary Tables 249 21 and 22). A burden test aggregating all UKB EGFr domain Cys-altering variants into a single 250 statistical test was strongly associated with stroke (OR [95% CI] = 2.86 [2.14, 3.82], p value = 6.29×10^{-10} ; AAF = 0.01%) (Table 2). In contrast to Cys-altering variants within EGFr domains, 251 252 Cys-altering variants outside of EGFr domains were not associated with stroke (OR [95% CI] =253 0.97 [0.46, 2.03], p value = 9.3×10^{-1} ; AAF = 0.039%) (Table 2). In order to rule out the 254 possibility that any missense variants in EGFr domains are associated with stroke, a test limited 255 to the most commonly altered (added or removed) amino acid in NOTCH3, serine (Ser), was 256 tested and did not show any evidence of association with stroke (OR [95% CI] = 0.98 [(0.8, 1.2], 257 p value = 0.084; AAF = 0.54%] (Table 2, Supplementary Table 23). Interestingly, a burden test 258 limited only to predicted loss of function (pLoF) variants (frameshift, splice variant, stop gain) 259 did not show significant evidence for association with stroke (OR [95% CI] = 1.38 [0.50, 3.85], p 260 value = 0.54; AAF = 0.019%) (Table 2, Supplementary Table 24). These results provide evidence to support the hypothesis that EGFr domain Cys-altering variants within NOTCH3 are 261 262 associated with stroke, in contrast to other protein-altering variants. 263 264 While hemorrhagic stroke represents a small proportion of the strokes reported in the UKB, the 265 set of Cys-altering variants were also tested for association with hemorrhagic stroke. A nominal 266 association with hemorrhagic stroke (OR [95% CI] = 3.61 [1.39, 9.34], p value = 8.31×10^{-3} ; AAF 267 0.025%) was observed, despite low statistical power.

268

238

239 240

241

242

243

244

245

269 Consistent with stroke risk, in MRI data of 35,344 UKB individuals, Cys-altering variants in 270 *NOTCH3* EGFr domains were strongly associated with WMH volume (p value = 3.7×10^{-13} ; with

carriers having 5.4 cm³ greater WMH volume than controls). These WMH differences were

271 272 strongest in the centrum semiovale and periventricular white matter (Supplementary Figure 7).

273 Additionally, we found strong WMH signal in the external capsule, which is known to be

274 involved in CADASIL. We found weaker evidence for association of NOTCH3 LoF variants

275 with WMH (effect size $[95\% \text{ CI}] = 6.8 \text{ cm}^3 [4.2 \text{ cm}^3, 10.9 \text{ cm}^3]$, p-value = 1.68×10^{-4}).

276

277 Prior studies have binned NOTCH3 EGFr domain Cys-altering variants in up to three distinct

278 severity or risk groups based on EGFr domain number [10, 14, 17]. Indeed, we observed a much

279 larger effect size for Cys-altering variants in high-risk EGFr domains 1-6 (OR [95% CI] = 29.5

[10.4, 83.8], p value = 1.37×10^{-7} ; AAF = 0.002%] compared to Cys-altering variants in EGFr 280

domains 7-34 (OR [95% CI] = 2.55 [1.87, 3.46], p value = 1.59×10^{-7} ; AAF = 0.098%) (Table 2, 281

282 Supplementary Table 23). These results are consistent with prior reports of differences in stroke

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34

283

284

285

286 287 288

289

290

291

292

293

294

295

296

297

298 299

300

301

302

303

304

305

306

307

308

309 310

311

312

313

314

315

316

317

318

319

320 321

322

323

324

325

326

327

328

8

17 June 2024 risk between EGFr domain risk groups not correlated with differences in signaling activity between EGFr risk groups [17]. Discussion This report describes the largest ExWAS of stroke conducted thus far in a South Asian population and highlights a Cys-altering missense variant in the 31st EGFr domain of NOTCH3 associated with stroke at a genome-wide level of statistical significance. This is the first study to report a genome-wide-significant association between NOTCH3 and stroke, a discovery enabled because NOTCH3 p.Arg1231Cys is markedly enriched in Pakistanis compared to Western European and non-Eurasian populations. Harbored in ~1 percent of Pakistani, p.Arg1231Cys is associated with a ~3-fold increased risk of hemorrhagic stroke. While some regional variability in the allele frequency is observed, p.Arg1231Cys is enriched in populations ranging from Turkey in West Asia to India in South Asia, suggesting a substantial contribution to stroke risk in millions of individuals across South Asia and West Asia as well as their global diaspora. *NOTCH3* was not previously associated with stroke in the largest GWAS predominantly consisting of European-derived participants [10]. In contrast to prior studies, both the discovery and replication cohorts in this study were South Asian, hence avoiding the bias encountered in studies with a European discovery cohort. Given the much lower allele frequency of p.Arg1231Cys in European populations, we observed a nominal association between p.Arg1231Cys and stroke in the UK Biobank study, showing a similar effect size as in South Asians. Nominal associations were also observed for phenotypes related to CADASIL, such as hypertension and depression. While brain images were not available for the Pakistani cohort, a strong association was observed between p.Arg1231Cys and quantitative brain MRI phenotypes in UKB data, such as white matter hyperintensity. Cys-altering mutations in proximal EGFr domains of NOTCH3 are known to cause autosomal dominant CADASIL, a rare highly penetrant distinct syndrome that includes early onset recurrent subcortical strokes. In contrast to classical CADASIL pathogenic variants, p.Arg1231Cys is in the 31st of 34 EGFr domains, appears to have more moderate penetrance, and is not obviously clinically distinguishable from more common multi-factorial forms of stroke in South Asians. The p.Arg1231Cys NOTCH3 variant is currently classified in ClinVar and recent reviews [14] as a variant of uncertain significance [20] or "low risk" [17]; however, based on our current findings, there is strong genetic, computational, and imaging evidence of pathogenicity for this variant despite reduced penetrance and severity compared to "classic" Cys-altering CADASIL pathogenic variants in EGFr domains 1 to 6 [14, 19]. Prior studies have debated if the mechanism whereby Cys-altering variants contribute to CADASIL-related pathology is through toxic aggregate gain of function (GoF) or a loss of normal signaling function (LoF). One study demonstrated excess risk of CADASIL-related phenotypes for Cys-altering variants in EGFr domains 1 to 34 [18], while other studies showed greater risk in EGFr domains 1 to 6 relative to EGFr domains 7 to 34 [14, 19]. A recent study showed evidence for expanding the high-risk tier of EGFr domains to include domains 8, 11, and 26 [17]. The current study provides three additional refinements. First, this study is the first to assess risk for LoF variants, and did not observe significant association signal (Table 2),

9

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

329 although the number of LoF carriers was small and thus power is limited to detect such

330 associations. These findings suggest that pathological mechanisms driven by dysfunctional

- disulfide bridge formation and subsequent protein misfolding and aggregation, as is commonly
- observed in CADASIL, may be more pathologic than simple LoF (haploinsufficiency) [19].
- 333 Second, we demonstrate association between p.Arg1231Cys with stroke, thus demonstrating that
- 334 CADASIL-related stroke is not uncommon as was previously thought. While prior studies have
- shown enrichment of p.Arg1231Cys in South Asians [21], and have used this information as
- evidence to classify p.Arg1231Cys variant as "low-risk" [17], the current study provides
- evidence contrary to that verdict. Furthermore, we have demonstrated a broader enrichment of
- the variant across the region, including multiple West Asian and South Asian populations. Third,
- the prior studies demonstrated a brain-wide association with WMH, while the current studyidentifies pathology focused in the external capsule and other brain regions known for
- 340 GADASIL pathology.
- 342

343 CADASIL is characterized by both ischemic and hemorrhagic strokes, although the factors that

344 contribute to the manifestation of one versus the other stroke type awaits further clarification [8].

345 Hemorrhagic stroke appears to represent a larger proportion of strokes in South Asia than in

Europe [2]. In this study, the p.Arg1231Cys association signal was stronger in PGR for

hemorrhagic strokes than for ischemic strokes, despite nearly two-fold larger ischemic stroke

case counts. In contrast, the UKB association signal appeared stronger for ischemic stroke,
 possibly due to low hemorrhagic stroke case count and thus statistical power in this cohort.

Statistical power in this conort.
 Statistical power issues aside, differences in manifestation of p.Arg1231Cys in South Asians

351 compared to Europeans may be attributable to differences in risk factors such as age, blood

352 pressure, diabetes, air pollution, smoking, medications such as anti-platelet and anti-coagulants

353 used to manage atherosclerotic disease, genetic background, or study-specific differences in

- 354 criteria to categorize stroke sub-types. Further research is needed to better ascertain the
- 355 mechanism behind cerebral arterial wall pathobiology and clinical presentation of ischemic
- 356 versus hemorrhagic stroke in p.Arg1231Cys carriers.
- 357

358 Currently there are no known effective preventive or therapeutic interventions for CADASIL or

359 less penetrant forms of *NOTCH3* related stroke. However, our analyses provide clues toward

360 their development. First, in contrast to our analyses of EGFr domain Cys-altering missense

361 variants in NOTCH3 that were significantly associated with stroke, predicted loss of function

362 variants that would be expected to not produce a functional protein were not significantly

363 associated with stroke. These observations suggest that targeting therapeutic interventions that

364 decrease expression of mutant protein (such as siRNA, antisense oligonucleotides, and CRISPR),

induce exon skipping of altered EGFr domains [22, 23], or accelerate removal of GOM may

- 366 prove beneficial for prevention and/or treatment [24].
- 367

368 Our analyses also suggest that p.Arg1231Cys is modestly associated with hypertension, although

369 p.Arg1231Cys association with stroke risk appears independent of hypertension or other stroke

370 risk factors such as smoking, age and sex. Animal models of CADASIL show decreased vascular

tone and contractility, most likely driven by loss of physiologic function and subsequent

degeneration of vascular smooth muscle cells (VSMCs) [25]. These observations suggest that

373 while management of hypertension and smoking cessation are effective modalities for primary

374 and secondary prevention of stroke, those with NOTCH3 mutation related strokes will need

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34

17 June 2024
375 additional therapeutic interventions, as existing hypertensive medications cannot restore VSMC
376 function.

376 377

378 A limitation of this study is the lack of brain imaging analysis for the Pakistani carriers, such that 379 specific brain regions affected by the ischemic and hemorrhagic strokes could be ascertained and 380 compared. In addition, we lacked more detailed clinical data such as presence of migraines and 381 longitudinal data of disease course including stroke recurrence, dementia, and depression. 382 Further characterization of p.Arg1231Cys carriers will be necessary to obtain better estimates of 383 penetrance as well as to identify distinguishing clinical or biomarker characteristics that may 384 have utility in early diagnosis, prevention and treatment, and for recommendations for cascade 385 screening in family members. Migraine symptoms typically precede stroke by 10+ years in 386 CADASIL patients [8], thus the combination of migraine with aura, depression and family 387 history of stroke could be sufficient evidence to prescribe NOTCH3 genetic testing. Finally, the 388 effect of LoFs on stroke risk will require larger sample sizes for more definitive comparison to 389 stroke risk of Cys-altering variants.

390

In conclusion, we identified a highly enriched Cys-altering variant in *NOTCH3* in South Asians that expands the phenotypic spectrum of CADASIL from rare and highly penetrant to common

and moderately penetrant. Based on our estimates, this single variant may be responsible for

~1.1% of all strokes combined and ~2.0% of hemorrhagic strokes in South Asians. Among 1.9
 billion South Asians there could be over 26 million carriers for the variant. Thus, this work has
 important implications for genetic screening and early identification of at-risk individuals, and
 the future opportunity for rationally targeted therapeutic interventions.

398 399

Methods

401 Summary

402

400

403 Details of methods below. Briefly, 75 K individuals were recruited and consented in Pakistan for 404 whole exome sequencing, including a stroke case:control discovery cohort of 31 K (including n 405 = 5,135 cases and n = 26,602 controls) sequenced by the Regeneron Genetics Center and a 406 follow-up cohort of 44 K (n=44,082), including 30 K with self-report stroke case:control status 407 used for replication and meta-analysis (n = 160 cases and n = 30,239 controls). ExWAS was 408 conducted for stroke and 4 overlapping stroke subtypes (intracerebral hemorrhage, subcortical 409 intracerebral hemorrhage, ischemic stroke, and partial anterior circulating infarct) in the 410 discovery cohort and combined in a meta-analysis of stroke with the replication cohort using 411 both single-variant and gene burden test models [26]. Population attributable fraction of stroke 412 for associated variants was calculated as based on the prevalence of mutation among cases and 413 odds ratio (OR) for risk of stroke in the discovery cohort using the standard definition [27]. 414 Consented callbacks were conducted in n = 128 individuals within families of homozygotes for

- 415 associated variants. For comparison and validation, analyses were conducted in UK Biobank data
- 416 using publicly available datasets and methodologies [28-31], including association analysis of
- 417 p.Arg1231Cys *NOTCH3* with stroke phenotypes in 380 K participants, and brain imaging
- 418 phenotypes in 35 K participants (Figure 1A).
- 419
- 420 Study Populations

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

421

422 This study focused on two distinct cohorts, including 75 thousand (K) individuals from the

- Pakistan Genomic Resource (PGR) and 370 K individuals from the United Kingdom Biobank
 (UKB) The PGR 75 K individuals were recruited and consented in Pakistan for whole exome
- 425 sequencing (WES) (n = 75.819), including a stroke case:control discovery cohort of 31 K (n =
- 426 31,737, including n = 5,135 cases and n = 26,602 controls) sequenced by the Regeneron Genetics
- 427 Center and a follow-up cohort of 44 K (n = 44,082), including 30 K with self-report stroke
- 428 case:control status used for replication and meta-analysis (n = 30,399, including n = 160 cases
- 429 and n = 30,239 controls). The remaining n = 13,684 in the follow-up cohort had sequence data
- 430 but not stroke case:control status known, including n = 6,067 produced by WES and n = 7,616
- 431 produced by whole genome sequencing (WGS). (Figure 1A).
- 432

433 Pakistan Genomic Resource (PGR)

434

435 PGR is a growing biobank that aims to enroll 1 million participants across Pakistan and as of 436 September 2023, ~250,000 participants across 48 clinical sites in 17 cities from all over Pakistan 437 have been enrolled. Following the success of a case-control study design in genetic studies 438 adopted by several international (e.g., Wellcome Trust case-control consortium) and regional 439 studies (e.g., PROMIS), PGR is a national consortium of several case-control studies focused on 440 50 distinct phenotypes, including: stroke, myocardial infarction, angiographically confirmed 441 coronary artery disease, heart failure, age-related macular degeneration, keratoconus, diabetic 442 retinopathy, glaucoma, asthma, chronic obstructive pulmonary disease (COPD), non-alcoholic 443 fatty liver disease (NAFLD), type-2 diabetes, chronic kidney disease, Alzheimer's disease, 444 Parkinson's disease, dementia, progressive multiple sclerosis, autism, Huntington's disease, hematological cancers, breast cancer, ovarian cancer, cancers of head and neck, esophageal 445 446 cancer, lung cancer, gastric cancer, colorectal cancer, melanoma, cancers of the urinary tract, 447 cervical cancer, prostate cancer, rheumatoid arthritis, systemic lupus erythematosus (SLE), 448 psoriatic arthritis, ankylosing spondylitis, osteoarthritis, scleroderma, juvenile arthritis, systemic sclerosis, inflammatory myositis, alopecia areata, acne rosacea, primary Sjogren's syndrome, 449 450 sarcoidosis, idiopathic pulmonary cholangitis, idiopathic pulmonary fibrosis, vitiligo, longevity / 451 healthy aging, and previously uncharacterized Mendelian disorder. For each of these phenotypes, 452 screening is carried out at specialized clinical sites across Pakistan by trained research medical 453 officers who review inclusion and exclusion criteria and approach eligible participants for 454 recruitment into PGR. In a similar manner, for each of the phenotypes, controls are frequency-455 matched to cases on sex and age (in 5-year bands). Controls are being recruited in the following 456 order of priority: (1) visitors of patients attending the out-patient department; (2) patients 457 attending the out-patient department for routine non-phenotype related complaints, or (3) non-458 blood related visitors. Following informed consent, both cases and controls are enrolled. 459 Research medical officers administer pre-piloted epidemiological questionnaires to participants 460 that seek a total of >200 items of information in relation to: ethnicity (e.g. personal and paternal 461 ethnicity, spoken language, place of birth and any known consanguinity); demographic 462 characteristics; lifestyle factors (e.g., tobacco and alcohol consumption, dietary intake and 463 physical activity); and personal and family history of disease; and medication usage. The Center 464 for Non-Communicable Diseases (CNCD), Pakistan serves as the sponsor and the coordinating 465 center of PGR. 466

12

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

467 Using standardized procedures and equipment, research officers obtain measurements of height,

468 weight, waist and hip circumference, systolic and diastolic blood pressure, and heart rate. Waist

- 469 circumference is assessed over the abdomen at the widest diameter between the costal margin
- and the iliac crest, and hip circumference is assessed at the level of the greater trochanters.
- 471 Information extracted from questionnaires and physical measurements is entered by two different
- 472 operators into the central database, which is securely held at CNCD, Karachi, Pakistan. Non-
- 473 fasting blood samples (with the time since last meal recorded) are drawn by phlebotomists from
- each participant and centrifuged within 45 min of venipuncture. A total of 29 ml of blood is drawn from each participant in 2×6 ml serum tubes and 3×5 ml EDTA tubes. Hence, a total of
- 475 drawn noin each participant in 2 × 0 in seruin tubes and 5 × 5 in EDTA tubes. Hence, a total of 476 five blood tubes are collected per participant, including serum, EDTA plasma and whole blood
- 477 which are all stored in cryogenic vials. All samples are stored temporarily at each recruitment
- 478 center at -20° C. Serum, plasma and whole blood samples are transported daily to the central
- 479 laboratory at CNCD where they are stored at -80°C. The long-term -80°C sample repository.
- 480 Measurements of total cholesterol, high-density lipoprotein-cholesterol, triglycerides, AST,
- 481 ALT, glucose, creatinine, and HbA1c (in a subset) are performed centrally using (Roche
- 482 Diagnostics GmbH, USA) in all study participants.
- 483

484 Research technicians trained in accordance with standard operating procedures in laboratories at

485 CNCD extracted DNA from leukocytes using a reference phenol-chloroform protocol. DNA

- 486 concentrations are determined. The yield of DNA per participant is typically between 600 and
- 487 800 ng/ μ l in a total volume of about 500 μ l. To minimize any systematic biases arising from
- 488 plate- or batch-specific genotyping error and/or nonrandom missingness, stock plates are used to
- 489 generate genotyping plates which contain a mixture of cases and controls along with negative
- and positive controls designed to address genotyping quality control (QC), plate identificationand orientation.
- 492

493 PGR has received approval by the relevant research ethics committee of each of the institutions

494 involved in participant recruitment, as well as centrally by the IRB board of the Center for Non-

495 Communicable Diseases which is registered with the National Institutes of Health, USA. PGR

496 has also been approved by the National Bioethics Committee, Islamabad Health Research

- 497 Institute, National Institutes of Health of Pakistan.
- 498

Eligibility criteria was defined as described below. Ischemic stroke sub-types in the PGR cohort
were defined using TOAST [32] and Oxfordshire [33] clinical criteria.

502 UK Biobank

503

504 The UK Biobank (UKB) cohort had detailed medical records and lifestyle data as described

505 online in the UKB Showcase (https://biobank.ndph.ox.ac.uk/showcase/) [28]. Stroke case:control

506 status was available in 380 K UK Biobank participants, of which 280 K also had smoking and

507 hypertension status (referred to as UKB replication cohort). A sub-cohort of n = 35,977 UKB

- 508 participants had brain MRI data which was produced and analyzed as described online
- 509 (https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/brain_mri.pdf) [29-31]. MRI images for n = 19
- 510 p.Arg1231Cys carriers were re-analyzed in order to identify brain regions affected (referred to as 511 UKP 25 K brain imaging achort) The description of phenotypes and methods for normalizing
- 511 UKB 35 K brain imaging cohort). The description of phenotypes and methods for normalizing
- the data, including rank-inverse normal transformation (RINT) are described online [28].

13

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

513 Exome Sample Preparation, Sequencing, and QC

- 514 Genomic DNA samples were transferred to the Regeneron Genetics Center from the CNCD and
- stored in an automated sample biobank at -80 °C before sample preparation. DNA libraries were
- 516 created by enzymatically shearing DNA to a mean fragment size of 200 bp, and a common Y-
- 517 shaped adapter was ligated to all DNA libraries. Unique, asymmetric 10 bp barcodes were added
- 518 to the DNA fragment during library amplification to facilitate multiplexed exome capture and
- 519 sequencing. Equal amounts of sample were pooled before overnight exome capture, with a
- slightly modified version of IDT's xGenv1 probe library; all samples were captured on the same
- 521 lot of oligonucleotides. The captured DNA was PCR amplified and quantified by quantitative
 522 PCR. The multiplexed samples were pooled and then sequenced using 75 bp paired-end reads
- PCR. The multiplexed samples were pooled and then sequenced using 75 bp paired-end reads
 with two 10 bp index reads on an Illumina NovaSeq 6000 platform on S4 flow cells. A total of n
- 524 = 42,695 samples were made available for processing. We were unable to process n = 1,948
- 525 samples, most of which failed QC during processing owing to low or no DNA being present.
- 526 A total of n = 40,747 samples were sequenced, of which n = 2,943 (7%) did not pass one or more
- 527 of our QC metrics and were subsequently excluded. Criteria for exclusion were as follows:
- 528 disagreement between genetically determined and reported sex (n = 900); high rates of
- 529 heterozygosity or contamination (VBID > 5%) (n = 709); low sequence coverage (less than 80%)
- 530 of targeted bases achieving $20 \times$ coverage) (n = 115); genetically identified sample duplicates
- 531 (n = 1,662 total samples); WES variants discordant with the genotyping chip (n = 43). The
- remaining n = 37,804 (37 K) samples were then used to compile a project-level VCF (PVCF) for
- 533 downstream analysis using the GL nexus joint genotyping tool. This final dataset contained n =
- 534 7,655,430 variants. Within this dataset of 37 K exomes, stroke case:control status was known for
- n = 31,737, referred to as the 31 K discovery cohort. The remaining n = 6,067 were part of the 41
- 536 K follow-up cohort.
- 537 Exome sequencing in the replication 30 K cohort (n = 39,399) was conducted by the CNCD
- using a publicly available protocol [34]. Briefly, blood derived DNA samples, with 10 to100 ng
- 539 concentration of initial genomic DNA, underwent hybridization and capture using Illumina
- 540 Rapid Cature Exome Kit or Agilents SureSelect Human Exon v2. Samples were denatured and
- amplified HiSeq v3 cluster chemistry and HiSeq 2000 or 2500 flowcells based on the
- 542 manufacturers protocol. Reads were aligned to the GRCh38 genome reference and variants were
- 543 called using GATK v.30 followed by variant recaliberation to remove false positive variants.
- 544
- 545 The remaining n = 7,616 exome samples of the 75 K PGR consisted of whole genome sequence
- 546 (WGS) data that produced a VCF subsequently filtered to include only variants in protein coding
- 547 sequence. WGS samples were sequenced and process as described in a publicly available
- 548 protocol (<u>https://www.nature.com/articles/s41586-021-03205-y</u>). Briefly, 30x whole genome
- 549 sequencing was performed using Illumina HiSeqX instruments. Reads were aligned to the
- 550 GRCh38 reference using BWA-align and variants were called using the publicly available
- 551 GotCloud pipeline (<u>https://genome.sph.umich.edu/wiki/GotCloud</u>), which includes QCing
- variants based on a support vector machine trained on specific site quality metrics.

553 Variant calling

14

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

- 554 The PGR discovery cohort WES data was reference-aligned using the OQFE protocol [35],
- which uses BWA MEM to map all reads to the GRCh38 reference in an alt-aware manner, marks
- 556 read duplicates and adds additional per-read tags. The OQFE protocol retains all reads and
- 557 original quality scores such that the original FASTQ is completely recoverable from the resulting
- 558 CRAM file. Single-sample variants were called using DeepVariant with custom exome
- parameters [35], generating a gVCF for each input OQFE CRAM file. These gVCFs were
- aggregated and joint-genotyped using GLnexus (v.1.3.1). All constituent steps of this protocol
- 561 were executed using open-source software. The PGR replication and follow-up cohort were
- analyzed using the publicly available GotCloud workflow
- 563 (https://genome.sph.umich.edu/wiki/GotCloud).

564 Identification of low-quality variants from sequencing using machine learning

565 Similar to other recent large-scale sequencing efforts, we implemented a supervised machine-

- 566 learning algorithm to discriminate between probable low-quality and high-quality variants [36,
- 567 37]. In brief, we defined a set of positive control and negative control variants based on the
- 568 following criteria: (1) concordance in genotype calls between array and exome-sequencing data;
- 569 (2) transmitted singletons; (3) an external set of likely 'high quality' sites; and (4) an external set
- 570 of likely 'low quality' sites. To define the external high-quality set, we first generated the
- 571 intersection of variants that passed QC in both TOPMed Freeze 8 and GnomAD v.3.1 genomes.
- 572 This set was additionally restricted to 1000 Genomes Phase 1 high-confidence SNPs from the
- 573 1000 Genomes Project [38] and gold-standard insertions and deletions from the 1000 Genomes
- 574 Project and a previous study [39], both available through the GATK resource bundle
 575 (https://gatk.broadinstitute.org/hc/en-us/articles/360035890811-Resource-bundle). To define the
- 6. For define the sector of the
- 577 Mendelian or duplicate discordant variants. Before model training, the control set of variants
- 578 were binned by allele frequency and then randomly sampled such that an equal number of
- 579 variants were retained in the positive and negative labels across each frequency bin. A support
- 580 vector machine using a radial basis function kernel was then trained on up to 33 available site
- 581 quality metrics, including, for example, the median value for allele balance in heterozygote calls
- and whether a variant was split from a multi-allelic site. We split the data into training (80%) and
- test (20%) sets. We performed a grid search with fivefold cross-validation on the training set to
- identify the hyperparameters that returned the highest accuracy during cross-validation, which
- 585 were then applied to the test set to confirm accuracy. This approach identified a total of n =
- 586 931,823 WES variants as low-quality, resulting in a dataset of n = 6,723,607 variants.

587 Variant annotation

588 Variants were annotated as described in a publicly available pipeline <u>38</u>. In brief, variants were

- annotated using Ensembl variant effect predictor, with the most severe consequence for each
- 590 variant chosen across all protein-coding transcripts. In addition, we derived canonical transcript
- annotations based on a combination of MANE, APPRIS and Ensembl canonical tags. MANE
- annotation was given the highest priority followed by APPRIS. When neither MANE nor
- APPRIS annotation tags were available for a gene, the canonical transcript definition of Ensembl
- was used. Gene regions were defined using Ensembl release 100. Variants annotated as stop
- 595 gained, start lost, splice donor, splice acceptor, stop lost or frameshift, for which the allele of

15

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

- 596 interest was not the ancestral allele, were considered predicted loss-of-function variants. Five
- 597 annotation resources were utilized to assign deleteriousness to missense variants: SIFT,
- 598 Polyphen2_HDIV, Polyphen2_HVAR, LRT, MutationTaster [40-43], and LRT, obtained using
- 599 dbNSFP [44]. Missense variants were considered 'likely deleterious' if predicted deleterious by
- all five algorithms, 'possibly deleterious' if predicted deleterious by at least one algorithm and
- 601 'likely benign' if not predicted deleterious by any algorithm.

602 Pakistan Genome Resource Statistical Analysis

603

ExWAS of SNPs with minor allele count > 5 in the 31 K PGR discovery cohort was conducted

- with 5 binary stroke phenotypes using REGENIE (v 3.1.1) [26] with age, age², sex, age*sex,
- exome batch, 10 genotyping array principal components (PCs), 10 common variant exome PCs
- and 10 rare variant exome PCs as covariates. The minimum of 1,000 cases was selected based on
- a power calculation [45] (1,000 cases; 25,000 controls; significance threshold 0.005; prevalence
- 0.0012; disease allele frequency 0.005; genotype relative risk 3.0; > 80% power). Follow-up
- analyses were conducted with the added covariates of hypertension and tobacco use, or as
- 611 environmental factors in a gene-by-environment interaction test using REGENIE [26]. Gene
- burden analysis was conducted using REGENIE with separate masks for pLoF, pLoF +
- 613 missense, pLoF + deleterious missense (as predicted by at least 1 of 5 algorithms), and pLoF +
- deleterious missense (as predicted by 5 of 5 algorithms). Analysis in the 61 K PGR meta-analysis
- 615 cohort, including 31 K discovery and 30 K replication cohorts, was conducted using REGENIE.
- 616

617 **PGR Population Genetic Analysis**

618

619 Using principal components (PCs) [46] and Uniform Manifold Approximation and Projection 620 (UMAP) [47] based analyses PGR and UKB South Asian sub-populations were mapped to 621 distinct groups or clusters. Specifically, we used the imputed genotypes to merge the PGR 622 dataset with UKB and 1000 genome datasets. Imputed data was used to maximize the number of 623 common variants between all three datasets. The Plink [48] "--bmerge" option was used to merge datasets. A minimal QC was applied to the merged genotypes to exclude variants with 624 625 MAF less than 5%, missing genotype rate greater than 10%, and Hardy Weinberg equilibrium P 626 value less than 5 x 10^{-5} . Variants mapping within the HLA region were excluded. Merged datasets were pruned for linkage disequilibrium ($r^2 > 0.25$). A total of 20 PCAs were calculated 627 in the merged data using the Plink -pca option. Calculated PCAs were imported to R and merged 628 629 with reported ethnicities or country of birth information. The first 6 PCs calculated on the 630 merged data were reduced to two dimensions using the UMAP package in R. The two

eigenvectors of UMAP were calculated using an alpha value of 1.1 and beta value of 0.8. Two

- eigenvectors were plotted along with ethnicity and country of birth labels using the Plotly
- package in R. UKB self-reported ethnicities or country of birth was confirmed to be highlycorrelated with data obtained from UMAP.
- 635

636 **Population Attributable Fraction**

- 637
- Estimation of the proportion of all strokes combined or hemorrhagic stroke in Pakistan
- 639 population attributable to p.Arg1231Cys was calculated using the formula [27],

16

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

640

641

642

$$AF_p = P_c \times AF_e = P_c \left(1 - \frac{1}{OR}\right)$$

643 where P_c is the prevalence of mutation among cases, AF_e is the attributable fraction in the 644 exposure, and *OR* was for risk of stroke (i.e., all stroke combined or hemorrhagic stroke) 645 comparing mutant vs wild type of p.Arg1231Cys in the discovery cohort.

646

647 OR was obtained directly from Supplementary Table 2. The related 95% confidence intervals
648 were constructed using bootstrap method with 10,000 resamples [49], which was implemented
649 with the command "Bootstrap" using Stata (College Station, Texas 77845 USA).

651 Recall by Genotype

652

650

653 A subset of carriers of NOTCH3 p.Arg1231Cys were contacted by the Center of Non-654 Communicable Diseases in Karachi Pakistan under protocols approved by the IRB committee of 655 the Center for Non-Communicable Diseases (NIH registered IRB 00007048). After obtaining 656 consent from the proband and from the family members, questionnaires regarding past medical 657 and family history were administered by trained research staff, in the local language. Physical 658 measurements such as height, weight, hip and waist circumference were obtained in the standing 659 position by using height and weight scales. Blood pressure and heart rate were recorded sitting 660 by using OMRON healthcare M2 blood pressure monitors. Non-fasting blood samples were collected from each participant in EDTA and Gel Tubes. Serum and plasma were separated 661 within 45 minutes of venipuncture. A random urine sample was also collected from each 662 663 participant. The samples were stored temporarily in dry ice in the field and transported to the 664 central laboratory based at CNCD and stored at -80 degrees Celsius. Measurements for total-665 cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, VLDL, AST, ALT and creatinine were obtained from serum samples using enzymatic assays. HbA1c was measured using a 666 667 turbidemetric assay in whole-blood samples (Roche Diagnostics). All measurements were done 668 at a central laboratory at CNCD. Statistical analysis comparing across genotypes was conducted 669 using the numpy library in Python 3.11.4.

670 671

672

PGR Stroke Case Control Definitions

673 Controls • 674 Inclusion • 675 No medical history of stroke, myocardial infarction (MI), coronary artery • 676 disease, heart failure (HF), valvular disease, or pacemaker 677 • Cases 678 Inclusion • 679 • General Criteria • Stroke: Diagnosis of 'Stroke' 680 681 Ischemic: Diagnosis of 'Ischemic stroke' 682 Hemorrhagic: Diagnosis of 'Hemorrhagic stroke' 0 683 Subcortical: Type of intracerebral hemorrhage = 'Subcortical'

17

Rodriguez-Flores et al.

NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34

	17 June 2024
684	 Parenchymal: Type of intracerebral hemorrhage =
685	Parenchymal
686	Oxfordshire Criteria
687	• Partial anterior circulation infarct (PACI): Partial anterior circulation
688	infarcts (PACI) stroke sub-type
689	• Posterior circulation infarction (POCI): Posterior circulation infarcts
690	POCI stroke sub-type
691 692	• Total anterior circulation infarct (TACI): Total anterior circulation infarcts TACI' stroke sub-type
693	• Lacunar infarct (LACI): Lacunar infarcts stroke sub-type
694	• TOAST Criteria
695	• Cardioembolism (CE): Cardioembolism ischemic stroke subtype
696	• CE probable: CE criteria, in addition diagnosis is made if the clinical
697	findings, neuroimaging data, and results of diagnostic studies are
698	consistent with one subtype and other etiologies have been excluded
699	• Large artery atherosclerosis (LAA): Large artery atherosclerosis
700	ischemic stroke subtype based on TOAST classification
701	• LAA probable: LAA criteria, in addition in addition diagnosis is made
702	if the clinical findings, neuroimaging data, and results of diagnostic
703	studies are consistent with one subtype and other etiologies have been
704	excluded
705	• Small artery atherosclerosis (SAA): Small artery atherosclerosis
706	ischemic stroke subtype
707	 SAA probable: SAA criteria, in addition in addition diagnosis is made
708	if the clinical findings, neuroimaging data, and results of diagnostic
709	studies are consistent with one subtype and other etiologies have been
710	excluded
711	
712 713	UK Biobank Stroke Case Control Definition
714	UK Biobank stroke case control definitions were based on ICD10 codes as follows.
715	
716	• Cases
717	• Inclusion
718	Phe10_I63, ICD10 3D: Cerebral infarction
719	 Phe10_I630, ICD10 4D: Cerebral infarction due to thrombosis of
720	precerebral arteries
721	 Phe10_I631, ICD10 4D: Cerebral infarction due to embolism of
722	precerebral arteries
723	 Phe10_I632, ICD10 4D: Cerebral infarction due to unspecified occlusion
724	or stenosis of precerebral arteries
725	 Phe10_I633, ICD10 4D: Cerebral infarction due to thrombosis of cerebral
726	arteries
727	 Phe10_I634, ICD10 4D: Cerebral infarction due to embolism of cerebral
728	arteries

Rodriguez-Flores et al. 18 NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024 729 Phe10 I635, ICD10 4D: Cerebral infarction due to unspecified occlusion 730 or stenosis of cerebral arteries 731 Phe10 I638. ICD10 4D: Other cerebral infarction 732 Phe10_I639, ICD10 4D: Cerebral infarction, unspecified . 733 Self-reported: SR 1583 ischaemic stroke . 734 Primary and secondary cause of death using above ICD codes. 735 Exclusion 0 736 Phe10 I636, ICD10 4D: Cerebral infarction due to cerebral venous 737 thrombosis, nonpyogenic 738 Controls 739 Inclusion • 740 Negative for the above codes • 741 Negative for Phe10 Z823, ICD10 4D: Family history of stroke 742 2. Exclusion: 743 Phe10 G45, ICD10 3D: Transient cerebral ischemic attacks and related 744 syndromes 745 Phe10_G458, ICD10 4D: Other transient cerebral ischemic attacks and related • 746 syndromes 747 Phe10_G459, ICD10 4D: Transient cerebral ischemic attack, unspecified • 748 749 750 Custom Burden Tests in UKB 450 K 751 752 Burden tests aim to boost statistical power by aggregating association signal across multiple rare 753 variants. Prior studies in human and animal models have debated the role of various variant 754 classes on NOTCH3 function, CADASIL pathology and patient prognosis, including experiments 755 designed to determine if the pathogenicity of CADASIL variants follows a loss of function (LoF) mechanism [8, 25, 50]. Using data from hundreds of missense and LoF variants in NOTCH3 756 757 observed in 450 K UKB participant exomes, burden tests were conducted to assess the impact of 758 LoF and missense variants. 759 760 Ten distinct gene burden tests of association with stroke were conducted using REGENIE [26], 761 divided into three distinct groups. The Group I tests assessed the impact of Cys-altering variants, 762 Group II tests assessed the impact of Ser-altering variants, and Group III tests assessed LoF and 763 all missense variants. Group I and II consisted of four distinct tests, including (1) a test of all 764 group variants in EGFr domains 1 to 34, (2) a test of all group variants in EGFr domains 1 to 6, 765 (3) a test of all group variants in EGFr domains 7 to 34, and (4) a test of all group variants outside of EGFr domains. The difference between Group I and Group II was Group I variants are 766

missense variants that either add or remove a Cysteine (Cys-altering), while Group II variants are
missense variants that either add or remove a Serine (Ser-altering). While the role of Cys-altering
variants in CADASIL is well known [15, 19, 20], Ser-altering variants were chosen based on

being the most common class of variants among *NOTCH3* variants in UKB 450 K exomes.

771 Group III consisted of two tests, including (1) a test limited to LoF variants and (2) a test limited

to LoF and missense variants.

773

774

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

19

775

776 777

Data Availability

- The primary data in this study not already presented in the manuscript and supplement consists
- of ExWAS summary statistics for 5 stroke phenotypes analyzed in the PGR cohort. This data is
- 780 publicly available in the GWAS Catalog under accessions GCST90432122, GCST90432123,
- 781 GCST90432124, GCST90432125, and GCST90432126.
- 782

Rodriguez-Flores et al. NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

20

Code Availability

Data collection and analysis software, tools, algorithms, and packages used in this
manuscript are publicly available in software repositories. Below is a list of the softwares
used, their versions, and contemporary links to public repositories.

789 Data Production

Read alignment was conducted using BWA MEM v.0.7.17. Variant calling was conducted
using Deep Variant v.0.10.0. Joint genotyping was conducted using GLnexus v1.3.1. Variant
deleteriousness was calculated using SIFT v.2011, Polyphen 2 v.2011, LRT v.2013,
MutationTaster v.4.3, and dbNSFP v.3.2. Single variant ExWAS and gene burden test of
PGR and UKB data was conducted using REGENIE v.3.1.3.

796 Data Analysis

797 Figures were plotted using R v.4.4.1. Data management was conducted using Python 798 v.3.11.4. Statistical tests in Table 1 were conducted using R stats library v.4.3.0. 799 Supplementary Figure 1 and 2 were produced using R UpSetR library v.1.4.0. Supplementary 800 Figures 3 and 4 were produced using R QQMAN library v.0.1.8. Supplementary Figure 5 801 was produced using R Plotly library v.4.10.1. Supplementary Figure 6 was produced using R 802 v.4.4.1. Supplementary Figure 7 was produced using ITK-SNAP v.3.8.0. Principal 803 Components Analysis was conducted using PLINK v.1.9. Uniform Manifold Approximation 804 and Projection was conducted using UMAP v.0.2.10.0. Power calculation was conducted 805 using GAS Power Calculator v.2017. Meta Analysis in Figure 3 was conducted using 806 METAL v.2011-03-25. MRI Image Analysis was conducted using FMRIB Software Library 807 (FSL) v.5.0.10 and FreeSurfer v.6.0. Alignment in Figure 2 was conducted using BLAST 808 v.2.14.

809

783

784

788

795

810

21

Rodriguez-Flores et al.

NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34

17 June 2024

811 References 812 813 1. Mills, M.C. and C. Rahal, The GWAS Diversity Monitor tracks diversity by disease in 814 real time. Nat Genet, 2020. 52(3): p. 242-243. 815 2. Collaborators, G.B.D.S., Global, regional, and national burden of stroke and its risk 816 factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. 817 Lancet Neurol, 2021. 20(10): p. 795-820. 818 3. Sherin, A., et al., Prevalence of stroke in Pakistan: Findings from Khyber Pakhtunkhwa 819 integrated population health survey (KP-IPHS) 2016-17. Pak J Med Sci, 2020. 36(7): p. 820 1435-1440. 821 4. Valcarcel-Nazco, C., et al., Variability in the use of neuroimaging techniques for 822 diagnosis and follow-up of stroke patients. Neurologia (Engl Ed), 2019. 34(6): p. 360-823 366. 824 5. Farooq, A., N. Venketasubramanian, and M. Wasay, Stroke Care in Pakistan. 825 Cerebrovasc Dis Extra, 2021. 11(3): p. 118-121. 826 6. Farooq, M.U., et al., The epidemiology of stroke in Pakistan: past, present, and future. Int 827 J Stroke, 2009. 4(5): p. 381-9. 828 7. Mullen, M.T., et al., Hospital-Level Variability in Reporting of Ischemic Stroke Subtypes 829 and Supporting Diagnostic Evaluation in GWTG-Stroke Registry. J Am Heart Assoc, 830 2023. **12**(24): p. e031303. 831 8. Chabriat, H., et al., *Cadasil*. Lancet Neurol, 2009. 8(7): p. 643-53. 832 9. Markidan, J., et al., Smoking and Risk of Ischemic Stroke in Young Men. Stroke, 2018. 833 **49**(5): p. 1276-1278. 834 10. Mishra, A., et al., Stroke genetics informs drug discovery and risk prediction across 835 ancestries. Nature, 2022. 611(7934): p. 115-123. Scott, E.M., et al., Characterization of Greater Middle Eastern genetic variation for 836 11. 837 enhanced disease gene discovery. Nat Genet, 2016. 48(9): p. 1071-6. 838 12. Wang, T., M. Baron, and D. Trump, An overview of Notch3 function in vascular smooth 839 muscle cells. Prog Biophys Mol Biol, 2008. 96(1-3): p. 499-509. 840 Duvaud, S., et al., Expasy, the Swiss Bioinformatics Resource Portal, as designed by its 13. 841 users. Nucleic Acids Res, 2021. 49(W1): p. W216-w227. 842 14. Rutten, J.W., et al., Broad phenotype of cysteine-altering NOTCH3 variants in UK 843 Biobank: CADASIL to nonpenetrance. Neurology, 2020. 95(13): p. e1835-e1843. 844 15. Rodriguez-Flores, J.L., et al., The QChip1 knowledgebase and microarray for precision 845 medicine in Qatar. NPJ Genom Med, 2022. 7(1): p. 3. 846 Hoffmann, T.J., et al., Genome-wide association analyses using electronic health records 16. 847 identify new loci influencing blood pressure variation. Nat Genet, 2017. 49(1): p. 54-64. 848 17. Hack, R.J., et al., Three-tiered EGFr domain risk stratification for individualized NOTCH3-small vessel disease prediction. Brain, 2023. 146(7): p. 2913-2927. 849 850 Cho, B.P.H., et al., Association of Vascular Risk Factors and Genetic Factors With 18. 851 Penetrance of Variants Causing Monogenic Stroke. JAMA Neurol, 2022. 79(12): p. 852 1303-1311. 853 19. Rutten, J.W., et al., The effect of NOTCH3 pathogenic variant position on CADASIL 854 disease severity: NOTCH3 EGFr 1-6 pathogenic variant are associated with a more 855 severe phenotype and lower survival compared with EGFr 7-34 pathogenic variant. 856 Genet Med, 2019. 21(3): p. 676-682.

22

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34

17 June 2024

857 20. ClinVar, N.C.f.B.I.

- Rutten, J.W., et al., *Archetypal NOTCH3 mutations frequent in public exome: implications for CADASIL*. Ann Clin Transl Neurol, 2016. 3(11): p. 844-853.
- Rutten, J.W., et al., *Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept.* Brain, 2016. **139**(Pt 4): p. 1123-35.
- 862 23. Gravesteijn, G., et al., *Naturally occurring NOTCH3 exon skipping attenuates NOTCH3*863 *protein aggregation and disease severity in CADASIL patients*. Hum Mol Genet, 2020.
 864 29(11): p. 1853-1863.
- 865 24. Ghezali, L., et al., *Notch3(ECD) immunotherapy improves cerebrovascular responses in*866 *CADASIL mice*. Ann Neurol, 2018. 84(2): p. 246-259.
- Belin de Chantemele, E.J., et al., *Notch3 is a major regulator of vascular tone in cerebral and tail resistance arteries*. Arterioscler Thromb Vasc Biol, 2008. 28(12): p. 2216-24.
- 869 26. Mbatchou, J., et al., *Computationally efficient whole-genome regression for quantitative*870 *and binary traits.* Nat Genet, 2021. 53(7): p. 1097-1103.
- 871 27. Greenland, S., *Applications of Stratified Analysis Methods*, in *Modern epidemiology:*872 *Third edition*. 2008, Lippincott Williams & Wilkins: Philadelphia. p. 295-297.
- 873 28. Backman, J.D., et al., *Exome sequencing and analysis of 454,787 UK Biobank*874 *participants*. Nature, 2021. **599**(7886): p. 628-634.
- 875 29. Benjamini, Y. and Y. Hochberg, *Controlling the False Discovery Rate: A Practical and*876 *Powerful Approach to Multiple Testing*. Journal of the Royal Statistical Society. Series B
 877 (Methodological) 1995. 57(1): p. 289-300.
- 878 30. Elliott, L.T., et al., *Genome-wide association studies of brain imaging phenotypes in UK*879 *Biobank.* Nature, 2018. 562(7726): p. 210-216.
- 31. Griffanti, L., et al., *BIANCA (Brain Intensity AbNormality Classification Algorithm): A new tool for automated segmentation of white matter hyperintensities.* Neuroimage, 2016.
 141: p. 191-205.
- Adams, H.P., Jr., et al., *Classification of subtype of acute ischemic stroke*. *Definitions for use in a multicenter clinical trial*. *TOAST*. *Trial of Org 10172 in Acute Stroke Treatment*.
 Stroke, 1993. 24(1): p. 35-41.
- Bamford, J., et al., *Classification and natural history of clinically identifiable subtypes of cerebral infarction*. Lancet, 1991. **337**(8756): p. 1521-6.
- Saleheen, D., et al., *Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity.* Nature, 2017. 544(7649): p. 235-239.
- 890 35. Olga Krasheninina, Y.-C.H., Xiaodong Bai, Aleksandra Zalcman, Evan Maxwell, Jeffrey
 891 G. Reid, William J. Salerno Jr., *Open-source mapping and variant calling for large-*892 scale NGS data from original base-quality scores. Biorxiv, 2020.
- 893 36. Lin, M., et al., Admixed Populations Improve Power for Variant Discovery and
 894 Portability in Genome-Wide Association Studies. Front Genet, 2021. 12: p. 673167.
- 895 37. Karczewski, K.J., et al., *The mutational constraint spectrum quantified from variation in*896 141,456 humans. Nature, 2020. 581(7809): p. 434-443.
- 897 38. Genomes Project, C., et al., *A global reference for human genetic variation*. Nature, 2015. 526(7571): p. 68-74.
- Mills, R.E., et al., *An initial map of insertion and deletion (INDEL) variation in the human genome*. Genome Res, 2006. 16(9): p. 1182-90.
- 901 40. Sim, N.L., et al., *SIFT web server: predicting effects of amino acid substitutions on proteins*. Nucleic Acids Res, 2012. 40(Web Server issue): p. W452-7.

Rodriguez-Flores et al.

23

NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

- 41. Adzhubei, I., D.M. Jordan, and S.R. Sunyaev, *Predicting functional effect of human*904 *missense mutations using PolyPhen-2*. Curr Protoc Hum Genet, 2013. Chapter 7: p.
 905 Unit7 20.
- 42. Chun, S. and J.C. Fay, *Identification of deleterious mutations within three human genomes.* Genome Res, 2009. **19**(9): p. 1553-61.
- 908 43. Steinhaus, R., et al., *MutationTaster2021*. Nucleic Acids Res, 2021. 49(W1): p. W446909 W451.
- 44. Liu, X., et al., *dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs.* Genome
 Med, 2020. 12(1): p. 103.
- 45. Skol, A.D., et al., *Joint analysis is more efficient than replication-based analysis for twostage genome-wide association studies.* Nat Genet, 2006. **38**(2): p. 209-13.
- 915 46. Price, A.L., et al., *Principal components analysis corrects for stratification in genome-*916 *wide association studies.* Nat Genet, 2006. 38(8): p. 904-9.
- McInnes, L.A., John% ASaul, Nathaniel% AGroßberger, Lukas% BJournal Name: Journal
 of Open Source Software, J.V. 3, and J.I. 29, UMAP: Uniform Manifold Approximation *and Projection.* Journal Name: Journal of Open Source Software; Journal Volume: 3;
 Journal Issue: 29, 2018: p. Medium: X; Size: 861.
- 48. Chang, C.C., et al., Second-generation PLINK: rising to the challenge of larger and
 922 richer datasets. Gigascience, 2015. 4: p. 7.
- 49. Efron, B. and R. Tibshirani, *Bootstrap Methods for Standard Errors, Confidence*924 *Intervals, and Other Measures of Statistical Accuracy.* Statistical Science, 1986. 1.
- 925 50. Joutel, A., et al., *Cerebrovascular dysfunction and microcirculation rarefaction precede* 926 white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease.
- 927 J Clin Invest, 2010. **120**(2): p. 433-45.
- 928
- 929
- 930

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

24

Acknowledgements

932
933
934

931

3 Supported by Regeneron Pharmaceuticals.

This research has been conducted using the UK Biobank Resource (project 26041). The 935 936 authors thank everyone who made this work possible, particularly the UK Biobank team, 937 their funders, the professionals from the member institutions who contributed to and 938 supported this work, and most especially the UK Biobank participants, without whom this 939 research would not be possible. The exome sequencing was funded by the UK Biobank 940 Exome Sequencing Consortium (Bristol Myers Squibb, Regeneron, Biogen, Takeda, Abbvie, 941 Alnylam, AstraZeneca and Pfizer). Ethical approval for the UK Biobank was previously 942 obtained from the North West Centre for Research Ethics Committee (11/NW/0382). 943

- 944 Disclosure forms provided by the authors are available with the full text of this article. 945
- 946 Drs. Rodriguez-Flores, Khalid, Shuldiner and Saleheen contributed equally to this article.
- 947 948

Inclusion and Ethics

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

25

949

950

951 The Institutional Review Board (IRB) at the Center for Non-Communicable Diseases (IRB:

- 952 00007048, IORG0005843, FWAS00014490) approved the study. All participants gave
- 953 written informed consent.
- 954
- 955

Rodriguez-Flores et al. NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

26

Formal analysis by Bin Ye (BY), Manav Kapoor (MK), Joshua Backman (JB), Gannie Tzoneva (ET), and Regeneron Genetics Center (RGC). Funding acquisition by DS, ARS, Aris Baras (AB), and RGC. Katia Karalis (KK), Aris Economides (AE), David D'Ambrosio (DDA), and Asif Rasheed (AR). Methodology by JLRF, SK, and RGC. Project administration by Thomas Coleman (TC), RGC, and AR. Visualization by JLRF, NP, FS, JM, and RGC. Writing of original draft by JLRF, SK, ARS, DS, PX, Sergio Fazio (SF), Wolfgang Liedtke (WL), John Danesh (JD), Ayeesha Kamal (AK), Philippe Frossard (PF), and RGC.

- 989 Writing review and editing by JLRF, PX, SK, ARS, DS, and RGC.
- 990
- 991
- 992
- 993

Author Contributions Statement

- 958 Conceptualization by Juan L. Rodriguez-Flores (JLRF), Shareef Khalid (SK), Alan R. Shuldiner 959 (ARS), and Danish Saleheen (DS). 960
- 961 Data curation by Nilanjana Banerjee (NB), Deepika Sharma (DeS), Michael Cantor (MC), John 962 Overton (JO), and Jeff Reid (JR).
- 963

956 957

964 965 (GT), Ellen Tsai (ET), Sahar Gelfman (SG), Tanima De (TD), Niek Verweij (NV), Luca A. Lotta (LAL), Aaron Zhang (AZ), Neelroop Parikshak (NP), Farshid Sepehrband (FS), Jonathan 966 967 Marchini (JM), Giovanni Coppola (GC), Sofia Castaneda (SC), Pengcheng Xun (PX), Ellen Tsai 968

- 969
- 970
- 971

972 Investigation by Silvio Alessandro DiGioia (SADG), Hector Martinez (HM), I-Chun Tsai (IT),

- 973 974
- 975
- 976 977
- 978 Resources by Muhammad Jahanzaib (MJ), Maleeha Zaman (MZ), Muhammad Rehan Mian
- 979 (MRM), Muhammad Bilal Liaqat (MBL), Khalid Mahmood (KM), Tanvir-us-Salam (TUS),
- Muhammad Hussain (MH), Ayeesha Kamal (AK), Javed Iqbal (JI), and Faizan Aslam (FA). 980
- 981

983 984

985 986

987

988

982 Software by RGC, JLRF, and SK. Supervision by DS and ARS. Validation by SK and JLRF.

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

27

Competing Interests Statement

- 994 995
- 996 Funding
- 997

Fieldwork for this study was funded by the Center for Non-Communicable Diseases, Pakistan.DNA sequencing was funded by Regeneron Pharmaceuticals Inc.

- 10001001 Employment
- 1001

JLRF, ARS, NB, DeS, MC, JO, JR, BY, MK, JB, GT, SG, TD, NV, LAL, AZ, NP, FS, JM, GC,
PX, AB, SADG, HM, IT, KK, AE, DDA, SF, WL, and TC are or were employees of Regeneron
Genetics Center LLC or Regeneron Pharmaceuticals Inc. and contributed to this manuscript as
part of their regular duties as salaried employees.

- 1008 ET and SC are or were student interns of Regeneron Genetics Center LLC or Regeneron
- 1009 Pharmaceuticals Inc. and contributed to this manuscript as part of their internship activites.
- 1010

1007

- 1011 AR, MJ, MZK, MRM, MBL, PF, and DS and SK are or were employees of the Center for Non-
- 1012 Communicable Disease and received salaried compensation for their contribution to this1013 manuscript.
- 1012

1015 Personal Financial Interests

1016

1017 JLRF, ARS, NB, DeS, MC, JO, JR, BY, MK, JB, GT, SG, TD, NV, LAL, AZ, NP, FS, JM, GC,

- 1018 PX, AB, SADG, HM, IT, KK, AE, DDA, SF, WL, TC are or were employees of Regeneron
- 1019 Genetics Center LLC or Regeneron Pharmaceuticals Inc. and received stock and stock options as
- 1020 part of their compensation as employees.
- 1021

1022 JLRF, ARS, DS, AB, and SK are named inventors on patent pending US 20230000897A1 that

- 1023 discloses methods of treating subjects having a cerebrovascular disease by administering
- 1024 Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) agents, and methods of identifying
- 1025 subjects having an increased risk of developing a cerebrovascular disease.
- 1026

Rodriguez-Flores et al.

28

NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

Tables

1027 1028

1029 Table 1. Baseline Characteristics of PGR Stroke Case-control Discovery Cohort¹ 1030

						Cas	e			
	~		~	_		p.Arg12	31Cys	Case I	Non-	
	Cas	e	Cont	rol		Carr	ier	Carr	ier	
	(n = 5, 1)	<u>135)</u>	(n = 26)	<u>,602)</u>		(n=10	<u>13)</u> 3	(n=4,9	<u>998)</u>	
	mean /	SD /	mean /	SD /	D I	mean /	SD /	mean /	SD /	D l
	<u>n</u>	% 0	n	% 0	P value	n	%0	n	% 0	P value
Female, n (%)	2,277	44.3	9,330	35.1	< 0.01	50	48.5	2,211	44.2	0.44
Age at enrolment, years	58.9	13.1	52.8	11.4	< 0.01	58.7	12.1	58.9	13.2	0.87
BMI, kg/m^2	25	3.9	27.5	4.4	< 0.01	24.6	3.4	24.9	3.9	0.35
Cholesterol mg/dL	175.3	55.5	172.1	48.2	< 0.01	174.8	49.1	175.3	55.7	0.94
LDL-C mg/dL	111.1	45.8	101.2	38.2	< 0.01	110.8	41.1	111.1	45.9	0.94
HDL-C mg/dL	37.8	12.7	35	10.8	< 0.01	38.8	12.1	37.8	12.7	0.43
Triglyceride mg/dL	140.3	81.8	185.7	120.1	< 0.01	126.3	62.7	140.5	82.3	0.04
Glucose, mg/dL	148.7	75.5	143.4	84.9	< 0.01	145.2	74.7	148.6	75.3	0.68
HbA1c %	6.9	1.8	6.6	2	< 0.01	7.3	1.9	6.9	1.9	0.15
Creatinine mg/dl	1.2	0.8	0.9	0.5	< 0.01	1.1	0.7	1.2	0.8	0.39
Tobacco or other										
stimulant user ²	1,850	36	9,242	34.7	< 0.01	32	31.1	0	0	0.34
Comorbidities										
Hypertension, n (%)	2,953	57.5	9,385	35.3	< 0.01	57	55.3	2,879	57.6	1
Diabetes, n (%)	1,195	23.3	5,766	21.7	< 0.01	29	28.2	1,157	23.1	0.29
Myocardial infarction,										
n (%)	371	6.2	622	2.3	< 0.01	5	4.9	215	4.3	0.98
Family history of										
Stroke, n (%)	324	6.3	0	0	< 0.01	14	13.6	306	6.1	< 0.01
Hypertension, n (%)	573	11.2	4,299	16.2	< 0.01	15	14.6	556	11.1	0.35
Diabetes, n (%)	349	6.8	5,199	19.5	< 0.01	11	10.7	334	6.7	0.16
Sudden death, n (%)	150	2.9	569	2.1	< 0.01	8	7.8	142	2.8	< 0.01

1031

1032 1. Shown are mean or total n and standard deviation or percentage for n = 5,135 cases versus n

= 26,602 controls on the left and n = 103 case p.Arg1231Cys NOTCH3 carriers versus n =1033

4,998 case non-carriers on the right. Comparison was conducted using R and p values are 1034 1035 shown from chi-square test for categorical variables (Fisher's exact test if cell size was <5) and from T-test for continuous variables. 1036

2.

Tobacco or other stimulants include cigarettes, paan (chewed betel leaf and areca nut), 1037 1038 naswar (snuff), gutka (chewing tobacco), huqqa (water pipe), chillum (hasish pipe).

- 3. 1039 Genotypes for the p.Arg1231Cys variant were not available for n=34.
- 1040

29

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

1041

1042 **Table 2. UKB Ischemic Stroke Association Across** *NOTCH3* **Variant Classes and Domains**¹

1043

NOTCH3	Effect	P value	AAF	Cases	Controls
Variant Class	[OR (95%CI)]		(%)	(RR RA AA)	(RR RA AA)
p.Arg1231Cys	3.38 (1.65,6.94)	8.8x10 ⁻⁴	0.02	9124 11 0	370986 139 0
EGFr 1-34 Cys-altering	2.86 (2.14,3.82)	6.3x10 ⁻¹⁰	0.01	9094 49 0	370693 709 1
EGFr 1-6 Cys-altering	29.51 (10.39,83.82)	1.4x10 ⁻⁷	0.002	9137 6 0	371394 9 0
EGFr 7-34 Cys-altering	2.55 (1.87,3.46)	1.6x10 ⁻⁷	0.098	9100 43 0	370702 700 1
Non-EGFr Cys-altering	0.97 (0.46,2.03)	9.3x10 ⁻¹	0.039	9136 7 0	371111 292 0
EGFr 1-34 Ser-altering	0.98 (0.8,1.2)	8.4x10 ⁻¹	0.54	9046 97 0	367355 4042 6
EGFr 1-6 Ser-altering	0.76 (0.23,2.56)	6.6x10 ⁻¹	0.018	9141 2 0	371271 132 0
EGFr 7-34 Ser-altering	0.99 (0.8,1.21)	8.9x10 ⁻¹	0.53	9048 95 0	367486 3911 6
Non-EGFr Ser-altering	0.84 (0.52,1.34)	4.5x10 ⁻¹	0.10	9128 15 0	370656 744 3
LoF variants	1.38 (0.50,3.85)	5.4x10 ⁻¹	0.019	9138 5 0	371261 142 0
LoF + any missense	1.09 (1.01,1.19)	3.3x10 ⁻²	3.30	8490 652 1	346648 24710 45

1044

Burden test with age, age², gender, 10 PCs as covariates was conducted using REGENIE to 1045 1. 1046 compare the association signal and effect size across variant classes and domains for 1047 ischemic stroke in n = 9,143 cases and n = 371,403 controls from UK Biobank. NOTCH3 1048 variant classes include the single variant association (p.Arg1231Cys) for reference at the top 1049 and burden tests limited to: Cys-altering variants in EGFr domains 1 to 34; Cys-altering variants in EGFr domains 1 to 6; Cys-altering variants in EGFr domains 7 to 34; Cys-altering 1050 1051 variants outside of EGFr domains; Ser-altering variants in EGFr domains 1 to 6; Ser-altering 1052 variants in EGFr domains 7 to 34; Ser-altering variants outside of EGFr domains; Loss of 1053 function (LoF) variants (defined as stop-gain, stop-loss, frameshift and splice-site variants 1054 with AAF <1%); and LoF and any missense variants (AAF <1%). Abbreviations: EGFr, epidermal growth factor-like repeat domain; AAF, alternate allele frequency; RR, reference 1055 1056 allele homozygote; RA, reference/alternate allele heterozygote; AA, alternate allele homozygote; 95% CI, 95% confidence interval 1057 1058

Rodriguez-Flores et al. *NOTCH3* p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

30

1059

1060

Figure Legends

1061 Figure 1. ExWAS Identifies *NOTCH3* p.Arg1231Cys Associated with Subcortical

Hemorrhagic Stroke in Pakistan Genome Resource 31 K Discovery Cohort. A. Flow chart 1062 1063 of the study described in this report. The discovery cohort consisted of a 31 K stroke case-control 1064 cohort (n = 31,737, including n = 5,135 stroke cases and n = 26,602 controls) from the Pakistan 1065 Genome Resource (PGR) (green boxes). A second PGR follow-up cohort of 44 K (n = 44,082) 1066 included 30 K participants with self-reported stroke case:control status for replication (n =1067 30,399, including n = 160 cases and n = 30,239 controls). UK Biobank data from 450 K sequenced participants was used for further analysis in a predominantly European ancestry 1068 population (blue boxes), 380 K of whom had stroke case:control status known (n = 9.143 cases 1069 1070 and n = 371,403 controls), and 35 K of whom had brain MRI data (n = 35,344). **B.** Manhattan plot of subcortical hemorrhagic stroke ExWAS in 31 K PGR discovery cohort participants (n = 1071 1072 1,388 cases and n = 26,602 controls) with likelihood ratio test $-\log_{10}$ p-values of calculated using 1073 REGENIE (y-axis) across chromosomes (alternating grey and black dots) and variants (x-axis). 1074 A single variant (NC_000019.10:g.15179052G>A) on chromosome 19 predicting a missense 1075 variant p.Arg1231Cys in NOTCH3 (pink diamond) exceeded the genome-wide significance threshold of 5×10^{-8} (red line). C. NOTCH3 locus zoom plot of subcortical stroke ExWAS. The 1076 1077 likelihood ratio test -log₁₀ p values for variants tested are shown on the y-axis. The 1078 p.Arg1231Cys variant is labeled as a diamond. Other variants (circles) are colored based on 1079 linkage disequilibrium with the reference variant in 1000 Genomes [38]. Gene exon (thick line) 1080 and intron (thin line) model shown below the graph. 1081

1082

Rodriguez-Flores et al. NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34

17 June 2024 1083 Figure 2. NOTCH3 EGFr Domain Disruption by p.Arg1231Cvs. Shown is NOTCH3 1084 p.Arg1231 in context of human NOTCH3 protein domains and cross-species alignment of 1085 NOTCH3 amino acid sequences. A. Human NOTCH3 Protein Domains. Shown is the position of 1086 the associated variant in context of transcript exons (top, alternating blue and purple with 1087 numbering) and protein domains (bottom, color coded). NOTCH3 can be divided into four major 1088 regions, from left-to-right the signal peptide (light blue), the extra-cellular domain (ECD, 1089 brown), the transmembrane domain (orange), and the intra-cellular domain (ICD, blue). The 1090 majority of the ECD is composed of 34 Epidermal Growth Factor-like repeat (EGFr) domains (in 1091 purple with white numbers). Domains involved in signaling are highlighted, including EGFr 1092 domains 10 to 11 involved in ligand binding (light purple, numbered), three cleavage domains 1093 (S1 in yellow, S2 in yellow with diagonal black stripes, S3 in yellow with black horizontal 1094 stripes), and three Lin12/NOTCH repeats (light green, numbered). The ICD contains the 1095 Recombination signal-binding protein for Ig of k region (RAM) domain for transcription factor 1096 interaction (green and white checkers), the Nuclear Localization Sequences (NLS, orange with 1097 black stripes), five Ankyrin repeats involved in signal transduction (green with white numbers), 1098 and the Proline, glutamic acid, serine, and threonine-rich (PEST) domain essential for 1099 degradation (green with white stripes). The p.Arg1231Cvs variant (red line top to bottom) 1100 removes a disulfide-bridge-forming cysteine in the 31st EGFr domain of the ECD, coded by the 1101 22nd exon. B. Cross-species Alignment of NOTCH3 (EGFr) Domain # 31 Amino Acid 1102 Sequences calculated using BLAST. Shown is an amino acid alignment of 31st EGFr domain of 1103 *NOTCH3* (human sequence amino acids 1205 to 1244), including (top-to-bottom) human 1104 reference, human p.Arg1231Cys mutant, chimpanzee (Pan troglodytes), mouse (Mus musculus), zebrafish (Danio rerio), western clawed frog (Xenopus tropicalis), and green sea turtle (Chelonia 1105 1106 *mvdas*), indicating conservation of the arginine (R) at position 1231 in mammals. Highly-1107 conserved cysteine (C) residues (normally 6 per EGFr) are highlighted in yellow.

1108 1109

32

Rodriguez-Flores et al. NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

- 1110 Figure 3. Forest Plot Showing Replication of *NOTCH3* p.Arg1231Cys Association with
- 1111 Stroke Across 61 K Pakistan Genome Resource Meta-Analysis. Shown is the cohort name,
- 1112 trait, odds ratio with 95% confidence interval, likelihood ratio test p value calculated using
- 1113 REGENIE\, alternate allele frequency, case count, and control count for five stroke phenotypes
- 1114 in the PGR 31 K discovery cohort (n = 5,135 stroke cases and n = 26,602 controls) (top), and
- 1115 Inverse Variance Weighted (IVW) Meta-Analysis using METAL of stroke in 61 K PGR Cohort,
- 1116 including 31 K PGR discovery cohort and 30 K PGR replication cohort (n = 160 cases and n =
- 1117 30,239 controls) subset of the 44 K PGR follow-up cohort (bottom).
- 1118
- 1119

Rodriguez-Flores et al. NOTCH3 p.Arg1231Cys is Markedly Enriched in South Asians and Associated with Stroke Version 34 17 June 2024

1120

1121

1122

1123



Figure 1

Α.



Signal Peptide Extracellular Transmembrane Intracellular S1 Cleavage S2 Cleavage S3 Cleavage Heterodimer (HD)

Epidermal Growth Factor-like repeat (EGFr) I Ligand-Binding EGFr I Lin12/NOTCH Repeat (LNR)

Recombination signal-binding protein for Ig of κ region (RAM) Ankyrin Repeat (ANK)

Α.

Nuclear Localization Sequence (NLS) Proline, glutamic acid, serine, and threonine-rich (PEST)

В. 1205 1244 1231 INECRSGACHAAHTRDCLODPGGGFRCLCHAGFSGPRCOT Human 1231 Arg (reference) INECRSGACHAAHTRDCLQDPGGGFCCLCHAGFSGPRCQT Human 1231 Cys (mutant) INECRSGACHAAHTRDCLQDPGGGFRCLCHAGFSGPRCQT Chimpanzee INECRPGACHAAHTRDCLQDPGGHFRCVCHPGFTGPRCQI Mouse INECLSNPCNPSNSLDCIQLPND-YQCVCKPGFTGRGCQS Zebrafish INECLSGPCHAQNTRHCVQLAND-YQCVCKSGYTGRRCQS Western clawed frog INECLAKPCLPQRTLDCVQGAND-FQCLCKPGYTGRRCQN Green sea turtle

Figure 2

Cohort	Trait	OR (95% CI)	P value	AAF	Cases (RR RA AA)	Controls (RR RA AA)
	Stroke	⊦∎⊣	4.92E-08	6.13E-03	4939 98 3	25619 271 2
	Ischemic stroke	┝╼┥	2.49E-03	5.64E-03	2540 42 2	25619 271 2
Discovery	Intracerebral hemorrhage	⊢ ⊷⊣	1.79E-08	5.82E-03	1451 44 0	25619 271 2
	Subcortical intracerebral hemorrhage		3.87E-09	5.84E-03	1313 43 0	25619 271 2
	Partial anterior circulation infarcts	⊢⊷⊣	4.84E-03	5.56E-03	1227 25 1	25619 271 2
		0 1 2 3 4 5 6				

Cohort	Trait	OR (95% CI)	P value	AAF	Cases	Controls
Discovery	Stroke	•	4.92E-08	6.13E-03	4939 98 3	25619 271 2
Replication	Stroke	├ ──── ┤	5.00E-03	0.00513	154 6 0	29935 302 2
IVW Meta-Analysis	Stroke	┝╼╌┥	7.79E-10	0.00576	5093 104 3	55617 586 4
		0 1 2 3 4 5 6 7 8				

Figure 3